SERUM INSTITUTE OF INDIA

In April 2026, Meiji Seika Pharma Co., Ltd. announced that its group company, KM Biologics Co., Ltd., has entered into a technology collaboration with Serum Institute of India Private Limited to develop and manufacture a Japanese encephalitis vaccine. The company also announced that it has achieved the first milestone under this collaboration.

In April 2026, Serum Institute of India and the University of Oxford signed a licensing agreement to advance the next-generation multi-stage malaria vaccine component (R78C), enabling global development and manufacturing to strengthen efforts in malaria prevention.

In April 2026, Serum Institute of India and VaxThera (Colombia) announced a strategic collaboration to strengthen vaccine development and health security in Colombia, focusing on joint programmes for manufacturing and supply of critical vaccines to support national immunisation efforts.

In March 2026, Serum Institute of India announced that Eveliqure Biotechnologies has entered into a strategic collaboration and licensing agreement with it for the development, manufacturing, and commercialisation of anti-diarrhoeal vaccines targeting key global pathogens.

In March 2026, Serum Institute of India and the University of Oxford has entered into an intellectual property license agreement with it to advance the development, manufacturing, and global supply of the ChAdOx1 NipahB vaccine candidate for emerging infectious diseases.

In January 2026, Serum Institute of India and the University of Oxford and CEPI have entered into a licensing and collaboration agreement with it to create the largest-ever investigational reserve of Rift Valley fever vaccine (ChAdOx1 RVF), with plans to manufacture up to 100,000 doses to support clinical trials and future outbreak preparedness.

In November 2025, Serum Institute of India announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for SIILTIBCY, a novel tuberculosis skin test, enabling its use for TB detection in the United Kingdom and strengthening its presence in regulated international markets.

In May 2025, SCHOTT Pharma, a pioneer in drug containment and delivery solutions, announced today that TPG, a leading global alternative asset management firm, has entered into a binding agreement to acquire a 35% stake in its joint venture SCHOTT Poonawalla from Serum Institute of India (SII).

In May 2024, The Serum Institute of India (SII), has invested strategically in IntegriMedical, securing a 20% stake in the company to propel Needle-Free Injection System technology forward.

In February 2024, Serum Institute has announced New Phase 3 Trial Data Confirm the Uniquely High Efficacy and Good Safety Profile of the R21/Matrix-M™ Malaria Vaccine in African Children

In January 2024, Serum Institute of India joins CEPI global network to boost production of affordable outbreak vaccines.

In November 2023, Serum Institute has announced to start Phase I & II trials of dengue vaccine in India.

In October 2023, WHO approves world’s 2nd malaria vaccine by Oxford-Serum Institute.

In August 2023, Serum Institute of India CEO, Mr. Adar Poonawalla received the ‘Udyog Mitra’ award from the Government of Maharashtra.

In July 2023, MenFive®, the first conjugate vaccine to protect against the five predominant causes of meningococcal meningitis in Africa, has been prequalified by the World Health Organization (WHO).

In July 2023, UK Minister Mr. George Freeman visits Serum Institute of India.

In May 2023, the International Society for Pharmaceutical Engineering (ISPE) awards Serum Institute of India, the 2023 Facility of the Year Category Award for Supply Chain and Social Impact.

In April 2023, Serum Institute restarts manufacturing of Covishield vaccine as Covid cases surge.

In April 2023, Serum Institute launches country’s first HPV vaccine, ‘CERVAVAC’. It has been jointly created by the Serum Institute of India and the Department of Biotechnology.

In April 2023, The University of Oxford-developed and Serum Institute of India (SII) manufactured and scaled up R21/Matrix-M malaria vaccine, leveraging Novavax’s adjuvant technology, has been licensed for use in Ghana by the country’s Food and Drugs Authority (FDA).

In April 2023, Serum Institute of Life Sciences announced to double up its investment in Biocon's unit to US$ 300 million. With this, Biocon's unit will also get access to SILS' 100 million vaccine doses annually.

In February 2023, Serum Institute of India announces centre of excellence in Hyderabad to tackle future pandemics.

In January 2023, Serum Institute of India launched the first made-in-India qHPV vaccine 'CERVAVAC'.

In January 2023, Serum Institute of India CEO Adar Poonawalla received ‘Dr. Patangrao Kadam Memorial Award’.

In September 2022, India’s first indigenously developed Quadrivalent Human Papillomavirus vaccine 'CERVAVAC' was announced for the prevention of cervical cancer. Serum Institute of India (SII), the Department of Biotechnology (DBT), the Biotechnology Industry Research Assistance Council (BIRAC), and the Bill and Melinda Gates Foundation collaborated to develop this vaccine.

In September 2022, Serum Institute of India received 'Happiest Workplace Award – 2022'.

Serum Institute of India (SII) plans to launch the country’s first indigenous HPV vaccine to combat cervical cancer in the near future.

In December 2021, Serum Institute of India pledged US$ 66.2 million to the University of Oxford to setup a research campus.

In November 2021, Serum Institute of India crossed the 1 billion doses of Covishield vaccine production milestone.

Serum Institute Life Sciences Private Limited (SILS) and Biocon Biologics Limited (BBL) announced a strategic alliance to develop antibodies for infectious diseases such as dengue, HIV, and others.

In June 2021, SII announced plans to launch Novavax's COVID-19 vaccine 'Covovax' in India by September 2021

Government of India signed a deal to procure 20 million doses of its COVID-19 vaccination.

Launched India’s first fully indigenously developed pneumococcal vaccine, 'Pneumosil'

Launched world’s first rabies human monoclonal antibody, recombinant

Launched oral polio vaccine

Acquired Bilthoven Biologicals, Netherlands

Launched Trivalent seasonal influenza vaccine

Launched injectable inactivated polio vaccine

Launched H1N1 influenza vaccine

Launched liquid pentavalent vaccine (DPT-HepB-Hib) (PENAVAC SD/PFS)

Launched Hib vaccine and BCG vaccine for bladder cancer

Launched BCG vaccine

Launched Hepatitis B vaccine

Launched MMR vaccine

Launched measles vaccine

Commenced production of DTP vaccine